GlassScriptPhysician profile
Andrew R Stowell
NPI 1790944312
$2,104.12
in general payments reported to CMS, 2019-2025
26 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $398 · 2022: $294 · 2023: $273 · 2024: $614 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.42 |
| Education | $206.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $334.11 | 2021-2025 | Austedo Xr, Uzedy |
| Abbvie INC. | $238.62 | 2021-2025 | |
| Alkermes, INC. | $237.92 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| W. L. Gore & Associates, INC. | $143.11 | 2025 | Gore Cardioform Septal Occluder |
| Janssen Pharmaceuticals, INC | $128.17 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Indivior INC. | $121.70 | 2021-2025 | Sublocade, Perseris |
| Lundbeck LLC | $111.60 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.51 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $94.11 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Corium, LLC | $87.35 | 2022-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $73.56 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $62.65 | 2021-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $49.72 | 2023-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $44.54 | 2022-2024 | |
| Sage Therapeutics, LLC | $34.62 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $33.03 | 2024-2025 | Brixadi |
| Merck Sharp & Dohme LLC | $30.87 | 2021-2023 | Belsomra |
| Axsome Therapeutics, INC. | $30.26 | 2024 | Auvelity |
| Almatica Pharma LLC | $24.34 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.26 | 2021 | |
| Eisai INC. | $17.59 | 2021 | |
| Vanda Pharmaceuticals INC. | $16.88 | 2021 | |
| Neurocrine Biosciences, INC. | $16.52 | 2024 | Ingrezza |
| Tris Pharma INC | $15.31 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.42 | 2024 | Quviviq |
| Bausch Health US, LLC | $14.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Stowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.